- PRODUCTS
-
UP.SIGHT™ 2nd GenNEW
Optimized For Proof Of Monoclonality, Colony Tracking, Confluency, & Titer Measurement -
F.SIGHT™ 2.0
Optimized For Rapid Dispensing of Fluorescent Cells -
C.SIGHT™ 2.0
Optimized for Powerful Dispensing of Unlabeled Cells -
B.SIGHT™
Optimized For Rapid Microbial Single-Cell Isolation and Cultivation -
F.SIGHT™ OMICS
Optimized For Single-Cell-Omics -
F.SIGHT™
Optimized For Affordability And Flexibility -
C.SIGHT™
Optimized for Affordable Cell Line Development -
Compare Products
Decide which one is right for you - Help Me Choose
-
UP.SIGHT™ 2nd GenNEW
- APPLICATIONS
- CUSTOMERS
- RESOURCES HUB
- COMPANY
- SHOP
Introducing the CYTENA Cell and Gene Therapy Tracker
Our clients are breaking new ground in cell and gene therapies, and we wanted to create an easy way to keep tabs on what this community is up to. That’s why we created a tool to track the current pipeline of cell and gene therapies across six core therapeutic areas, including those already approved for market.
What’s in the Tracker?
The tracker contains information on every cell and gene therapy currently in phase I of the drug discovery pipeline or higher. It also includes therapies currently on the market and select therapies that are in preclinical development. The following information is covered for each therapy:
Company name
Refers to the company that developed the drug, not the parent company. Partnerships are indicated by a “/” between company names which are ordered alphabetically.
Product code
A code or investigational name given by the company during the research and clinical trial phases.
Brand name
Proprietary name given to a therapy by its manufacturer once it has been granted market approval.
Therapy type
Gene Therapy or Cell Therapy.
Therapy subtype
Allogeneic or Autologous for Cell Therapies; In vivo or Ex vivo for Gene Therapies.
Approval year
Indication
The specific condition or disease for which a drug or treatment is prescribed. e.g., Multiple Myeloma.
Therapeutic area
Category of medicine focused on a particular group of similar diseases. e.g., Oncology.
Why Use the Tracker?
The field of cell and gene therapies is exploding. What was once a tiny pool of pioneering therapies has expanded into a vast landscape of novel technologies across diverse indications. This makes keeping up with the field challenging but essential for understanding trends and knowing where you sit compared to the competition.
The tracker is an invaluable tool for identifying gaps in the market and areas that are saturated. As such, it is essential for guiding strategic decision-making and establishing competitive and realistic timelines for your drug discovery projects.
CGT Market at a Glance
Proportion of Therapies Per Stage
Market Breakdown by Therapeutic Area
How to Use the Tracker
The tracker is perfect for scrolling to get an overview of the landscape and for honing in on a particular indication or therapy type to gain specific insights. Want to see what a key competitor is up to? Simply sort by whatever column heading is most relevant and scroll down to find what you’re looking for.
How Do We Populate the Tracker?
We scour diverse authoritative sources to ensure this tracker is as comprehensive as possible, including:
- Clinical trial databases
- Company websites
- Research papers
- Press releases
- Company social media
- Market reports
Where possible, we verify the information using multiple sources, with clinical trial databases and company websites taking precedence.
How Often Is It Updated?
We update the tracker every quarter to make sure you never miss a beat.
Last updated: August 1, 2024
Did we miss something? Let us know what you’d like to see added to the tracker.
Last updated: August 1, 2024
Did we miss something? Let us know what you’d like to see added to the tracker.
How CYTENA Instruments Accelerate Cell and Gene Therapy Development
At CYTENA, we support companies developing the next generation of cell and gene therapies. Our UP.SIGHT is a dual single-cell dispenser and imager that streamlines cell line development and derisks workflows by providing >99.99% probability of clonal derivation. This instrument uses microfluidics to ensure gentle dispensing, making it perfect for working with induced pluripotent stem cells that are sensitive to mechanical stress.
If you want to join the automation revolution that so many top companies already benefit from, then the C.STATION from CYTENA is your ultimate solution. The C.STATION provides end-to-end automation for cell line development that integrates confluency screening, antibody titer measurements, and much more. This means you get pure, high-performing cell lines quickly, while freeing up time and resources for other tasks.
Ready to see your therapy on the CYTENA cell and gene therapy tracker with the rest? Visit our product page to discover how our comprehensive suite of instruments can help streamline your cell line development workflow.
Disclaimer: While we endeavor to include all CGT therapies currently in the pipeline, some may have been omitted by mistake.